Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial

Q2 Medicine
Jennifer H. Tang , Nicole L. Davis , Amanda H. Corbett , Lameck Chinula , Mackenzie L. Cottrell , Yasaman Zia , Gerald Tegha , Frank Z. Stanczyk , Stacey Hurst , Mina C. Hosseinipour , Lisa B. Haddad , Athena P. Kourtis
{"title":"Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial","authors":"Jennifer H. Tang ,&nbsp;Nicole L. Davis ,&nbsp;Amanda H. Corbett ,&nbsp;Lameck Chinula ,&nbsp;Mackenzie L. Cottrell ,&nbsp;Yasaman Zia ,&nbsp;Gerald Tegha ,&nbsp;Frank Z. Stanczyk ,&nbsp;Stacey Hurst ,&nbsp;Mina C. Hosseinipour ,&nbsp;Lisa B. Haddad ,&nbsp;Athena P. Kourtis","doi":"10.1016/j.conx.2020.100027","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz.</p></div><div><h3>Study design</h3><p>We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point.</p></div><div><h3>Results</h3><p>The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46–0.79] at 1 month to 0.27 (90% CI 0.12–0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations &lt;<!--> <!-->180 pg/mL (the previously suggested minimum threshold concentration for efficacy).</p></div><div><h3>Conclusions</h3><p>Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations &lt;<!--> <!-->180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users.</p></div><div><h3>Implications</h3><p>Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.</p></div>","PeriodicalId":10655,"journal":{"name":"Contraception: X","volume":"2 ","pages":"Article 100027"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.conx.2020.100027","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraception: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590151620300101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Objectives

Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz.

Study design

We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point.

Results

The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46–0.79] at 1 month to 0.27 (90% CI 0.12–0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy).

Conclusions

Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users.

Implications

Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.

Abstract Image

Abstract Image

依非韦伦对马拉维左炔诺孕酮植入物使用者同时使用30 个月左炔诺孕酮浓度的影响:一项随机临床试验的亚分析
我们的主要目的是比较在植入后30 个月,服用抗逆转录病毒依非韦伦或未服用依非韦伦的左炔诺孕酮植入物使用者之间的几何平均左炔诺孕酮浓度。我们的次要目的是评估依非韦伦使用左炔诺孕酮植入物的妊娠率。研究设计:我们对42名马拉维妇女进行了亚组分析,这些妇女随机接受左炔诺孕酮植入,作为母体随机临床试验的一部分。我们的子集包括30名服用依非韦伦的艾滋病毒感染妇女和12名未服用依非韦伦的艾滋病毒感染妇女。每3个 月进行一次尿妊娠试验,在植入后第3天和第1、3、6、12、18、24、27、30个月进行血清左炔诺孕酮试验。计算依非韦伦使用者和非依非韦伦使用者在每个时间点的左炔诺孕酮几何平均浓度。结果依非韦伦服用者各时间点左炔诺孕酮几何平均浓度均低于非依非韦伦服用者;依法韦伦使用者的几何平均比值:非依法韦伦使用者在1 个月时为0.60[90%置信区间(CI) 0.46-0.79],在植入后30 个月时为0.27 (90% CI 0.12-0.61)。同时使用左炔诺孕酮和依非韦伦的60年以上妇女中没有发生妊娠,尽管有11名妇女的左炔诺孕酮浓度很高。180 pg/mL(先前建议的最低有效阈值浓度)。结论头孢韦伦服用者左炔诺孕酮浓度低于非依非韦伦服用者,同时使用依非韦伦和左炔诺孕酮植入物的服用者中有三分之一的左炔诺孕酮浓度低于非依非韦伦。180 pg / mL。依非韦伦使用者可能需要继续评估左炔诺孕酮植入物的避孕效果。在42名使用左炔诺孕酮植入物避孕的马拉维妇女中,服用抗逆转录病毒依非韦伦的妇女血清左炔诺孕酮浓度低于未服用依非韦伦的妇女。然而,在60年的随访中,没有一个服用依非韦伦的妇女怀孕。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Contraception: X
Contraception: X Medicine-Obstetrics and Gynecology
CiteScore
5.10
自引率
0.00%
发文量
17
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信